Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Modulating PKCα Activity to Target Wnt/β-Catenin Signaling in Colon Cancer.

Dupasquier S, Blache P, Picque Lasorsa L, Zhao H, Abraham JD, Haigh JJ, Ychou M, Prévostel C.

Cancers (Basel). 2019 May 18;11(5). pii: E693. doi: 10.3390/cancers11050693.

2.

A Short SOX9 Peptide Mimics SOX9 Tumor Suppressor Activity and Is Sufficient to Inhibit Colon Cancer Cell Growth.

Blache P, Canterel-Thouennon L, Busson M, Verdié P, Subra G, Ychou M, Prévostel C.

Mol Cancer Ther. 2019 Aug;18(8):1386-1395. doi: 10.1158/1535-7163.MCT-18-1149. Epub 2019 May 15.

PMID:
31092563
3.

Quantifying circulating cell-free DNA in humans.

Meddeb R, Dache ZAA, Thezenas S, Otandault A, Tanos R, Pastor B, Sanchez C, Azzi J, Tousch G, Azan S, Mollevi C, Adenis A, El Messaoudi S, Blache P, Thierry AR.

Sci Rep. 2019 Mar 26;9(1):5220. doi: 10.1038/s41598-019-41593-4.

4.

A Cell Model Suitable for a High-Throughput Screening of Inhibitors of the Wnt/β-Catenin Pathway.

Grimaldi M, Boulahtouf A, Prévostel C, Thierry A, Balaguer P, Blache P.

Front Pharmacol. 2018 Oct 11;9:1160. doi: 10.3389/fphar.2018.01160. eCollection 2018.

5.

The dose-dependent effect of SOX9 and its incidence in colorectal cancer.

Prévostel C, Blache P.

Eur J Cancer. 2017 Nov;86:150-157. doi: 10.1016/j.ejca.2017.08.037. Epub 2017 Oct 6. Review.

PMID:
28988015
6.

SOX9 is an atypical intestinal tumor suppressor controlling the oncogenic Wnt/ß-catenin signaling.

Prévostel C, Rammah-Bouazza C, Trauchessec H, Canterel-Thouennon L, Busson M, Ychou M, Blache P.

Oncotarget. 2016 Dec 13;7(50):82228-82243. doi: 10.18632/oncotarget.10573.

7.

Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors.

Lapierre M, Linares A, Dalvai M, Duraffourd C, Bonnet S, Boulahtouf A, Rodriguez C, Jalaguier S, Assou S, Orsetti B, Balaguer P, Maudelonde T, Blache P, Bystricky K, Boulle N, Cavaillès V.

Oncotarget. 2016 Apr 12;7(15):19693-708. doi: 10.18632/oncotarget.7564.

8.

Applying ecological and evolutionary theory to cancer: a long and winding road.

Thomas F, Fisher D, Fort P, Marie JP, Daoust S, Roche B, Grunau C, Cosseau C, Mitta G, Baghdiguian S, Rousset F, Lassus P, Assenat E, Grégoire D, Missé D, Lorz A, Billy F, Vainchenker W, Delhommeau F, Koscielny S, Itzykson R, Tang R, Fava F, Ballesta A, Lepoutre T, Krasinska L, Dulic V, Raynaud P, Blache P, Quittau-Prevostel C, Vignal E, Trauchessec H, Perthame B, Clairambault J, Volpert V, Solary E, Hibner U, Hochberg ME.

Evol Appl. 2013 Jan;6(1):1-10. doi: 10.1111/eva.12021. Epub 2012 Nov 16.

9.

MiniSOX9, a dominant-negative variant in colon cancer cells.

Abdel-Samad R, Zalzali H, Rammah C, Giraud J, Naudin C, Dupasquier S, Poulat F, Boizet-Bonhoure B, Lumbroso S, Mouzat K, Bonnans C, Pignodel C, Raynaud P, Fort P, Quittau-Prévostel C, Blache P.

Oncogene. 2011 Jun 2;30(22):2493-503. doi: 10.1038/onc.2010.621. Epub 2011 Feb 7.

PMID:
21297661
10.

A new mechanism of SOX9 action to regulate PKCalpha expression in the intestine epithelium.

Dupasquier S, Abdel-Samad R, Glazer RI, Bastide P, Jay P, Joubert D, Cavaillès V, Blache P, Quittau-Prévostel C.

J Cell Sci. 2009 Jul 1;122(Pt 13):2191-6. doi: 10.1242/jcs.036483. Epub 2009 Jun 9.

11.

KLF4 regulation in intestinal epithelial cell maturation.

Flandez M, Guilmeau S, Blache P, Augenlicht LH.

Exp Cell Res. 2008 Dec 10;314(20):3712-23. doi: 10.1016/j.yexcr.2008.10.004. Epub 2008 Oct 21.

12.

CEACAM1, a SOX9 direct transcriptional target identified in the colon epithelium.

Zalzali H, Naudin C, Bastide P, Quittau-Prévostel C, Yaghi C, Poulat F, Jay P, Blache P.

Oncogene. 2008 Nov 27;27(56):7131-8. doi: 10.1038/onc.2008.331. Epub 2008 Sep 15.

PMID:
18794798
13.

Defective claudin-7 regulation by Tcf-4 and Sox-9 disrupts the polarity and increases the tumorigenicity of colorectal cancer cells.

Darido C, Buchert M, Pannequin J, Bastide P, Zalzali H, Mantamadiotis T, Bourgaux JF, Garambois V, Jay P, Blache P, Joubert D, Hollande F.

Cancer Res. 2008 Jun 1;68(11):4258-68. doi: 10.1158/0008-5472.CAN-07-5805.

14.

Sox9 regulates cell proliferation and is required for Paneth cell differentiation in the intestinal epithelium.

Bastide P, Darido C, Pannequin J, Kist R, Robine S, Marty-Double C, Bibeau F, Scherer G, Joubert D, Hollande F, Blache P, Jay P.

J Cell Biol. 2007 Aug 13;178(4):635-48.

15.
16.

SOX9 is an intestine crypt transcription factor, is regulated by the Wnt pathway, and represses the CDX2 and MUC2 genes.

Blache P, van de Wetering M, Duluc I, Domon C, Berta P, Freund JN, Clevers H, Jay P.

J Cell Biol. 2004 Jul 5;166(1):37-47.

17.

Characterization of two novel forms of the rat sulphonylurea receptor SUR1A2 and SUR1BDelta31.

Gros L, Trapp S, Dabrowski M, Ashcroft FM, Bataille D, Blache P.

Br J Pharmacol. 2002 Sep;137(1):98-106.

18.

alpha-Endosulfine, a new entity in the control of insulin secretion.

Bataille D, Héron L, Virsolvy A, Peyrollier K, LeCam A, Gros L, Blache P.

Cell Mol Life Sci. 1999 Oct 1;56(1-2):78-84. Review.

PMID:
11213264
19.

Characterization of low-affinity binding sites for glibenclamide on the Kir6.2 subunit of the beta-cell KATP channel.

Gros L, Virsolvy A, Salazar G, Bataille D, Blache P.

Biochem Biophys Res Commun. 1999 Apr 21;257(3):766-70.

PMID:
10208857
20.

Miniglucagon (glucagon 19-29), a potent and efficient inhibitor of secretagogue-induced insulin release through a Ca2+ pathway.

Dalle S, Smith P, Blache P, Le-Nguyen D, Le Brigand L, Bergeron F, Ashcroft FM, Bataille D.

J Biol Chem. 1999 Apr 16;274(16):10869-76.

21.

Miniglucagon: a local regulator of islet physiology.

Dalle S, Blache P, Le-Nguyen D, Le Brigand L, Bataille D.

Ann N Y Acad Sci. 1998 Dec 11;865:132-40.

PMID:
9928005
22.

Molecular cloning and tissue distribution of rat sarcosine dehydrogenase.

Bergeron F, Otto A, Blache P, Day R, Denoroy L, Brandsch R, Bataille D.

Eur J Biochem. 1998 Nov 1;257(3):556-61.

23.

[Post-translational maturation of proglucagon: variations in tissues and regulation pathways].

Bataille D, Dalle S, Blache P, Bergeron F.

Journ Annu Diabetol Hotel Dieu. 1998:127-40. Review. French. No abstract available.

PMID:
9773615
24.

Cloning and tissue distribution of a new rat olfactory receptor-like (OL2).

Blache P, Gros L, Salazar G, Bataille D.

Biochem Biophys Res Commun. 1998 Jan 26;242(3):669-72.

PMID:
9464275
25.

Endoprotease regulation of miniglucagon production.

Bataille D, Blache P, Bergeron F.

Ann N Y Acad Sci. 1996 Dec 26;805:1-8; discussion 8-9. Review. No abstract available.

PMID:
8993388
26.

Immunological detection of prohormone convertases in two different proglucagon processing cell lines.

Blache P, Le-Nguyen D, Boegner-Lemoine C, Cohen-Solal A, Bataille D, Kervran A.

FEBS Lett. 1994 May 9;344(1):65-8.

27.

Miniglucagon production from glucagon: an extracellular processing of a hormone used as a prohormone.

Blache P, Kervran A, Le-Nguyen D, Bataille D.

Biochimie. 1994;76(3-4):295-9. Review.

PMID:
7819338
28.

Endopeptidase from rat liver membranes, which generates miniglucagon from glucagon.

Blache P, Kervran A, Le-Nguyen D, Dufour M, Cohen-Solal A, Duckworth W, Bataille D.

J Biol Chem. 1993 Oct 15;268(29):21748-53.

29.

Diurnal profile of oxyntomodulin-like immunoreactivity in duodenal ulcer patients.

Le Quellec A, Kervran A, Blache P, Ciurana AJ, Bataille D.

Scand J Gastroenterol. 1993 Sep;28(9):816-20.

PMID:
8235438
30.

Inhibition of gastric acid secretion by oxyntomodulin and its 19-37 fragment in the conscious rat.

Jarrousse C, Carles-Bonnet C, Niel H, Sabatier R, Audousset-Puech MP, Blache P, Kervran A, Martinez J, Bataille D.

Am J Physiol. 1993 May;264(5 Pt 1):G816-23.

PMID:
8498507
31.

[Oxyntomodulin, a new hormonal marker of intestinal malabsorption syndromes].

Le Quellec A, Kervran A, Blache P, Ciurana AJ, Bataille D.

Rev Med Interne. 1993;14(10):982. French.

PMID:
8009075
32.

Oxyntomodulin-like immunoreactivity: diurnal profile of a new potential enterogastrone.

Le Quellec A, Kervran A, Blache P, Ciurana AJ, Bataille D.

J Clin Endocrinol Metab. 1992 Jun;74(6):1405-9.

PMID:
1592887
33.

Miniglucagon [glucagon-(19-29)] is a component of the positive inotropic effect of glucagon.

Pavoine C, Brechler V, Kervran A, Blache P, Le-Nguyen D, Laurent S, Bataille D, Pecker F.

Am J Physiol. 1991 May;260(5 Pt 1):C993-9.

PMID:
1852111
34.

Glucagon-(19-29), a Ca2+ pump inhibitory peptide, is processed from glucagon in the rat liver plasma membrane by a thiol endopeptidase.

Blache P, Kervran A, Dufour M, Martinez J, Le-Nguyen D, Lotersztajn S, Pavoine C, Pecker F, Bataille D.

J Biol Chem. 1990 Dec 15;265(35):21514-9.

35.

Metabolic clearance rates of oxyntomodulin and glucagon in the rat: contribution of the kidney.

Kervran A, Dubrasquet M, Blache P, Martinez J, Bataille D.

Regul Pept. 1990 Oct 29;31(1):41-52.

PMID:
2270317
36.

[Glucagon is processed to the (19-29) fragment at the level of the hepatocyte membrane].

Blache P, Kervran A, Dufour M, Martinez J, Le-Nguyen D, Lotersztajn S, Pavoine C, Pecker F, Bataille D.

C R Acad Sci III. 1989;308(17):467-72. French.

PMID:
2499405
37.

Oxyntomodulin and glicentin: brain-gut peptides in the rat.

Blache P, Kervran A, Bataille D.

Endocrinology. 1988 Dec;123(6):2782-7.

PMID:
3197645
38.
39.

Glucagon and related peptides. Molecular structure and biological specificity.

Bataille D, Blache P, Mercier F, Jarrousse C, Kervran A, Dufour M, Mangeat P, Dubrasquet M, Mallat A, Lotersztajn S, et al.

Ann N Y Acad Sci. 1988;527:168-85. Review. No abstract available.

PMID:
3291691
40.

Distribution of oxyntomodulin and glucagon in the gastrointestinal tract and the plasma of the rat.

Kervran A, Blache P, Bataille D.

Endocrinology. 1987 Aug;121(2):704-13.

PMID:
3595539

Supplemental Content

Loading ...
Support Center